Hims & Hers and Novo Nordisk are partners again, just weeks after Novo sued the telehealth giant for selling compounded GLP-1s.
Hims & Hers is planting its flag in new overseas markets; on U.S. soil, it's navigating a GLP-1s fight against Big Pharma's branded blockbusters.
Hims & Hers' Dr. Craig Primack explains why personalized care, not just GLP-1s, is the key to lasting weight loss success.
With a pharma giant in its corner, WeightWatchers is mounting a comeback, relying on FDA-approved GLP-1 medications.
Novo Nordisk ends its Wegovy deal with Hims & Hers, citing safety concerns as the telehealth firm pushes back.
Hims & Hers and Novo Nordisk are teaming to expand affordable access to weight loss treatments, launching a bundled Wegovy offering.
Sign Up to Our Newsletter
